Roivant Asia Cell Therapy Holdings

Roivant Asia Cell Therapy Holdings is a Roivant subsidiary that served as the legal entity behind Cytovant, a cell therapy venture launched with Sinovant Sciences to develop and commercialize cellular immunotherapies in Asia. The company was established to build an East Asia-focused cell therapy business spanning development, manufacturing, and commercialization. Its disclosed pipeline centered on licensed and partnered immuno-oncology assets from Medigene, including a T cell receptor therapy against NY-ESO-1, a dendritic cell vaccine targeting WT1 and PRAME, and discovery collaborations for two additional TCR programs tailored for East Asian patients. Public information suggests the entity remains part of Roivant's subsidiary structure, but there is little evidence of an active standalone operating presence today.